|Systematic (IUPAC) name|
|Mol. mass||413.55 g/mol
563.64 g/mol (tartrate)
| (what is this?)
Lasofoxifene (INN) (proposed tradename Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published online November 4th in The Journal of the National Cancer Institute.
In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.
On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn. Lasofoxifene was approved in the EU under the brand name Fablyn by the EMEA in March 2009.
In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.
- Gennari L, Merlotti D, Martini G, Nuti R (2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opin Investig Drugs 15 (9): 1091–103. doi:10.1517/13543718.104.22.1681. PMID 16916275.
- Fablyn - lasofoxifene
- Lednicer D, Emmert DE, Lyster SC, Duncan GW (September 1969). "Mammalian antifertility agents. VI. A novel sequence for the preparation of 1,2-disubstituted 3,4-dihydronaphthalenes". J. Med. Chem. 12 (5): 881–5. doi:10.1021/jm00305a038. PMID 5812203.
- Gennari L, Merlotti D, Nuti R (2010). "Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene". Clin Interv Aging 5: 19–29. PMC 2817938. PMID 20169039.
- Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles R, Zanchetta J, Kendler D, Neven P, Eastell R, the PEARL Study Investigators (2010). "Lasofoxifene in Postmenopausal Women with Osteoporosis". N Engl J Med 362 (8): 686–696. doi:10.1056/NEJMoa0808692. PMID 20181970.
- "Reference site for lasofoxifene information". Anakena Internet Services SL. Retrieved 2008-03-18.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|